TEX264

Testis-expressed protein 264 · Q9Y6I9 · TEX264 on Sugi Atlas →

723 patent compounds predicted against TEX264, 675 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL11913669	1.00	1/20
SCHEMBL22852443	1.00	1/20
SCHEMBL13091225	0.84	1/20
SCHEMBL22852405	0.79	1/20
SCHEMBL13091224	0.71	1/20
SCHEMBL11820603	0.70	1/20
SCHEMBL12418656	0.70	1/20
SCHEMBL11819211	0.69	1/20
SCHEMBL11818941	0.68	1/20
SCHEMBL12418650	0.68	1/20
Furosemide (SCHEMBL9811)	0.67	1/20
Furosemide (SCHEMBL428921)	0.67	1/20
SCHEMBL22852478	0.67	1/20
SCHEMBL22852414	0.67	1/20
Furosemide (SCHEMBL230297)	0.66	1/20
Furosemide (SCHEMBL1109955)	0.66	1/20
Furosemide (SCHEMBL1824236)	0.66	1/20
Furosemide (SCHEMBL2519788)	0.66	1/20
Furosemide (SCHEMBL2838147)	0.66	1/20
Furosemide (SCHEMBL2953945)	0.66	1/20

Clinical trials — most relevant to TEX264 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients	PHASE1/PHASE2	WITHDRAWN
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies	PHASE1/PHASE2	WITHDRAWN
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer	PHASE1/PHASE2	WITHDRAWN
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	PHASE1/PHASE2	SUSPENDED
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1	PHASE1/PHASE2	COMPLETED
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers	PHASE2	COMPLETED
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer	PHASE2	WITHDRAWN
Combination Immunotherapy Targeting Melanoma	PHASE1/PHASE2	RECRUITING
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy	PHASE2	COMPLETED
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma	PHASE1	RECRUITING
Dose Escalation Study of Immunomodulatory Nanoparticles	PHASE1	ACTIVE_NOT_RECRUITING
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1	PHASE1	COMPLETED
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)	PHASE1	COMPLETED
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors	PHASE1	COMPLETED
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1	PHASE1	COMPLETED
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy	PHASE1	WITHDRAWN
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)	PHASE1	COMPLETED
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1	PHASE1	COMPLETED
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies	PHASE1	UNKNOWN
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Testicular Torsion	nan	COMPLETED
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects	nan	WITHDRAWN
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma	nan	RECRUITING
Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer	nan	RECRUITING
RNA Cloning and Visualization in Human Atherosclerosis	nan	COMPLETED
Children and Adult Hemophagocytic Syndrome (HLHa)	nan	COMPLETED
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TEX264 binder may also engage these)

Protein	Name	Similarity
E9Q137	—	1.000	E9Q137 →
Q8C0R7	—	0.978	Q8C0R7 →
A4D2P6	—	0.977	A4D2P6 →
Q5SNT2	—	0.975	Q5SNT2 →
A2VDW6	—	0.975	A2VDW6 →
Q8CC12	—	0.974	Q8CC12 →
Q0QWG9	—	0.973	Q0QWG9 →
F1MLB4	—	0.972	F1MLB4 →
Q69Z89	—	0.972	Q69Z89 →
Q3TAA7	—	0.971	Q3TAA7 →
Q96F46	—	0.971	Q96F46 →
Q5MNU5	—	0.971	Q5MNU5 →
Q6PRD1	—	0.971	Q6PRD1 →
Q5T848	—	0.971	Q5T848 →
Q3KR56	—	0.971	Q3KR56 →
Q12770	—	0.971	Q12770 →
Q8C190	—	0.970	Q8C190 →
Q5BKX5	—	0.970	Q5BKX5 →
A6QM06	—	0.970	A6QM06 →
P97492	—	0.970	P97492 →
Q8VEF1	—	0.970	Q8VEF1 →
Q4R4I0	—	0.970	Q4R4I0 →
Q9BST9	—	0.970	Q9BST9 →
Q95K25	—	0.969	Q95K25 →
Q9H091	—	0.969	Q9H091 →
Q9GZP1	—	0.969	Q9GZP1 →
Q8N9W5	—	0.969	Q8N9W5 →
P97260	—	0.969	P97260 →
Q9Y2B5	—	0.969	Q9Y2B5 →
O43566	—	0.969	O43566 →